FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293581462> ?p ?o ?g. }

• W4293581462 endingPage "152089" @default.
• W4293581462 startingPage "152089" @default.
• W4293581462 abstract "Long-term efficacy and safety of tocilizumab (TCZ) in adult-onset Still's disease (AOSD) mostly derive from small case series. Herein we report a registry-based study investigating TCZ efficacy and safety in a cohort of patients with AOSD evaluated by clinical and serum inflammatory markers as well as drug retention rate analysis. This is an international multicentre study analyzing data from patients with AOSD regularly enrolled in the AIDA registry. TCZ efficacy was evaluated between baseline and last follow-up assessment in terms of changes in the Pouchot score and laboratory findings. Drug-retention rate was estimated by the Kaplan-Meier method, while Cox-regression analysis was employed to detect potential predictive factors of treatment withdrawal. Data from 31 patients (15 men, 16 women) refractory to the conventional therapies and treated with TCZ were extracted from the AIDA registry. Mean ± SD time of treatment duration with TCZ was 24.32 ± 20.57 months. Median (IRQ) Pouchot score significantly decreased throughout the study period (p=0.001) with a significant difference between baseline [2.00 (4.00)] and 6 month-follow-up [0.00 (0.00)] (p=0.003) and between baseline and last follow-up assessment [0.00 (0.00)] (p=0.032), while no differences were observed between 6 month-evaluation and last follow-up assessment (p=0.823). Similarly, laboratory parameters significantly decreased from baseline to the last follow-up visit. With regard to drug survival, cumulative TCZ retention rate at 12-, 24-, and 36-month follow-up visit were 83.1%, 71.7% and 63.7%, respectively, without significant differences between biologic naïve patients and those previously treated with other biologics (p=0.329). Likewise, no significant differences were observed between chronic articular course of AOSD and other types of disease course (p=0.938) or between patients co-administered with conventional immunosuppressants and patients receiving TCZ as monotherapy (p=0.778). Cox-regression analysis identified no variable associated with a higher hazard of treatment withdrawal. Treatment was discontinued in 9 patients due to long-term remission (n=4), adverse events (n=2), loss of efficacy (n=1), non-medical reason (n=1) and unspecified cause (n=1). Mean glucocorticosteroids daily dose significantly decreased from baseline (18.36 ± 24.72 mg) to the last follow-up assessment (4.02 ± 4.99 mg, p=0.003). TCZ allows control of disease activity as well as normalization of serum inflammatory markers in both systemic and chronic articular form of AOSD. Additionally, TCZ displays an excellent drug retention rate while minimizing the risk of long-term exposure to corticosteroids." @default.
• W4293581462 created "2022-08-30" @default.
• W4293581462 creator A5003838655 @default.
• W4293581462 creator A5004973079 @default.
• W4293581462 creator A5007341235 @default.
• W4293581462 creator A5008206258 @default.
• W4293581462 creator A5014898810 @default.
• W4293581462 creator A5015866814 @default.
• W4293581462 creator A5018175672 @default.
• W4293581462 creator A5018764793 @default.
• W4293581462 creator A5018866927 @default.
• W4293581462 creator A5019875049 @default.
• W4293581462 creator A5020328511 @default.
• W4293581462 creator A5022961442 @default.
• W4293581462 creator A5023519590 @default.
• W4293581462 creator A5023952807 @default.
• W4293581462 creator A5027801988 @default.
• W4293581462 creator A5030868203 @default.
• W4293581462 creator A5031904681 @default.
• W4293581462 creator A5032284644 @default.
• W4293581462 creator A5033339606 @default.
• W4293581462 creator A5035912090 @default.
• W4293581462 creator A5036741091 @default.
• W4293581462 creator A5037162928 @default.
• W4293581462 creator A5037295594 @default.
• W4293581462 creator A5037325027 @default.
• W4293581462 creator A5040038857 @default.
• W4293581462 creator A5040306344 @default.
• W4293581462 creator A5044956066 @default.
• W4293581462 creator A5048440937 @default.
• W4293581462 creator A5050728699 @default.
• W4293581462 creator A5051871418 @default.
• W4293581462 creator A5052441250 @default.
• W4293581462 creator A5053439941 @default.
• W4293581462 creator A5054065266 @default.
• W4293581462 creator A5054792352 @default.
• W4293581462 creator A5058658304 @default.
• W4293581462 creator A5063387918 @default.
• W4293581462 creator A5065247060 @default.
• W4293581462 creator A5065425218 @default.
• W4293581462 creator A5066151951 @default.
• W4293581462 creator A5066642738 @default.
• W4293581462 creator A5075515457 @default.
• W4293581462 creator A5076878098 @default.
• W4293581462 creator A5085007757 @default.
• W4293581462 creator A5085265927 @default.
• W4293581462 creator A5085360040 @default.
• W4293581462 creator A5087309422 @default.
• W4293581462 creator A5089837214 @default.
• W4293581462 creator A5090463803 @default.
• W4293581462 creator A5091129729 @default.
• W4293581462 creator A5091247371 @default.
• W4293581462 creator A5091277812 @default.
• W4293581462 date "2022-12-01" @default.
• W4293581462 modified "2023-10-14" @default.
• W4293581462 title "Efficacy and safety of tocilizumab in adult-onset Still's disease: Real-life experience from the international AIDA registry" @default.
• W4293581462 cites W1502588534 @default.
• W4293581462 cites W1614943507 @default.
• W4293581462 cites W1931386434 @default.
• W4293581462 cites W2008945784 @default.
• W4293581462 cites W2017213437 @default.
• W4293581462 cites W2050446994 @default.
• W4293581462 cites W2074391948 @default.
• W4293581462 cites W2093875641 @default.
• W4293581462 cites W2120852203 @default.
• W4293581462 cites W2146620925 @default.
• W4293581462 cites W2163296212 @default.
• W4293581462 cites W2294104147 @default.
• W4293581462 cites W2415396904 @default.
• W4293581462 cites W2537495580 @default.
• W4293581462 cites W2777894919 @default.
• W4293581462 cites W2801327004 @default.
• W4293581462 cites W2887530283 @default.
• W4293581462 cites W2891385015 @default.
• W4293581462 cites W2894765079 @default.
• W4293581462 cites W2909739147 @default.
• W4293581462 cites W2913532246 @default.
• W4293581462 cites W2925874700 @default.
• W4293581462 cites W3031381028 @default.
• W4293581462 cites W3033472194 @default.
• W4293581462 cites W3036899835 @default.
• W4293581462 cites W3083091322 @default.
• W4293581462 cites W3093132132 @default.
• W4293581462 cites W3116053639 @default.
• W4293581462 cites W3117927760 @default.
• W4293581462 cites W3171235404 @default.
• W4293581462 cites W4252641574 @default.
• W4293581462 cites W4293429475 @default.
• W4293581462 doi "https://doi.org/10.1016/j.semarthrit.2022.152089" @default.
• W4293581462 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36063578" @default.
• W4293581462 hasPublicationYear "2022" @default.
• W4293581462 type Work @default.
• W4293581462 citedByCount "7" @default.
• W4293581462 countsByYear W42935814622022 @default.
• W4293581462 countsByYear W42935814622023 @default.
• W4293581462 crossrefType "journal-article" @default.
• W4293581462 hasAuthorship W4293581462A5003838655 @default.
• W4293581462 hasAuthorship W4293581462A5004973079 @default.

• next